Knight Therapeutics Inc. continues to show positive momentum following recent regulatory news.
Knight Therapeutics Inc. (GUD.TO) has seen a notable increase in its stock price this week, rising 4.54% over the past week and an impressive 83.25% year-to-date. This uptick comes after a significant announcement regarding the approval of one of its key products.
Advertisement
Knight Therapeutics Inc.
GUD.TO
GUD.TO
Knight Therapeutics Inc.
WealthAwesomeMarket cap
$1.06B
P/E
72.2x
52W high
$11.00
52W low
$5.66
1W change
+4.54%
Beta
-0.01
Analyst Price Targets
Based on analyst covering GUD · as of Sep 17, 2026
Wall Street analysts forecast GUD stock price to rise 3.3% over the next 12 months.
Consensus
NeutralBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$11.19
+3.3% Upside
Current Price
C$10.83
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GUD's historical volatility
30-Day Vol
22.8%
Annualized
90-Day Vol
26.9%
Annualized
Trend (90d)
+45.4%
Annualized drift
90d Mean
C$12.74
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$11.43 | C$10.57 – C$12.37 |
| 60 trading days | C$12.07 | C$10.80 – C$13.49 |
| 90 trading days | C$12.74 | C$11.11 – C$14.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors should consider the implications of Knight Therapeutics' recent regulatory approval in Brazil and its strong performance metrics while being mindful of the stock's relatively high P/E ratio.
Knight Therapeutics' stock has risen 83.25% year-to-date.
With a current price of C$10.68, Knight Therapeutics is trading near the upper end of its 52-week range of C$5.66 to C$11.00.
Bull case
The recent regulatory approval for NIKTIMVO® in Brazil could boost Knight Therapeutics' revenue, increasing investor confidence and potentially driving the stock price higher.
Bear case
Despite the positive news, the high P/E ratio of 72.2 suggests that the stock may be overvalued compared to its earnings. This poses risks if future performance doesn't meet investor expectations.
Price Action Overview
Advertisement
Knight Therapeutics Inc. (GUD.TO) closed at C$10.68, remaining unchanged in today's trading session. Over the past week, the stock has gained 4.54%, reflecting positive sentiment following the recent regulatory news.
Company News Catalyst
On October 6, 2026, Knight Therapeutics announced the regulatory approval of its product NIKTIMVO® in Brazil. This news likely contributed to the recent increase in share price, as investors react positively to the potential for greater market access and revenue generation.
Technical Picture
The technical indicators for Knight Therapeutics show a bullish trend. The stock is currently trading above its 50-day moving average of C$9.90, indicating potential upward momentum. The 200-day moving average stands at C$8.13, showcasing a significant increase of 31.4% compared to the current price. With a 52-week range of C$5.66 to C$11.00, the stock is trading at 94% of its range, suggesting it is nearing its peak. The beta of -0.01 indicates that the stock is less volatile than the market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
